<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078685</url>
  </required_header>
  <id_info>
    <org_study_id>NL62017.078.17</org_study_id>
    <nct_id>NCT04078685</nct_id>
  </id_info>
  <brief_title>Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias</brief_title>
  <acronym>COBRA-PATH</acronym>
  <official_title>Contact-Force-Sensing-Based Radiofrequency Catheter Ablation in Paroxysmal Supraventricular Tachycardias: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this single-center prospective randomized controlled trial is to assess the&#xD;
      superiority of contact-force-(CF)-sensing-based approach compared to conventional&#xD;
      (non-CF-sensing) approach in the catheter ablation of PSVTs, and to investigate the safety of&#xD;
      open-irrigated, contact-force-sensing ablation catheters (used in a &quot;non-irrigated&quot; mode) in&#xD;
      these procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Multiple studies have demonstrated the importance of adequate catheter-tissue contact in the&#xD;
      creation of effective lesions during radiofrequency catheter ablation. The development of&#xD;
      contact-force(CF)-sensing catheters have contributed significantly to improve clinical&#xD;
      outcomes in atrial fibrillation 3-18. However CF-sensing technology is not used in the&#xD;
      ablation of paroxysmal supraventricular tachycardia. Although PSVT ablation with the&#xD;
      conventional approach (non-irrigated, non-CF-sensing catheters) is considered a relatively&#xD;
      low-risk procedure with fairly high success rate (short-and long-term) 1,2,19, we hypothesize&#xD;
      that contact-force sensing can further improve the outcomes of these procedures. Based on the&#xD;
      results of studies on atrial fibrillation ablation (mentioned above) we believe that&#xD;
      CF-sensing could similarly improve such important parameters as radiofrequency (RF)&#xD;
      application number/time, total procedure time, and fluoroscopy time in cases of PSVT&#xD;
      ablations, as well. In addition CF-sensing could also further improve acute&#xD;
      success/recurrence rates of PSVT ablation, and might also be capable to further diminish&#xD;
      complication risk.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      The primary objective of the present study is to demonstrate the superiority of&#xD;
      contact-force-sensing in the ablation of AVNRT and WPW-AVRT as assessed by the improvement in&#xD;
      the number and duration of radiofrequency applications compared with the conventional&#xD;
      ablation approach.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      Secondary objectives of the study are the followings:&#xD;
&#xD;
        -  to demonstrate that contact-force-sensing catheters are superior in terms of total&#xD;
           procedure duration and fluoroscopy times in the case of AVNRT/WPW-AVRT ablation.&#xD;
&#xD;
        -  to show that the use of contact-force sensing catheters is non-inferior to conventional&#xD;
           catheters (without contact-force-sensing) in terms of acute/long-term procedural success&#xD;
           and procedural safety (major/minor complication rate) of AVNRT/WPW-AVRT ablations.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      All patients above 18 years without structural heart disease being referred for&#xD;
      electrophysiological study and potential treatment with radiofrequency catheter ablation of&#xD;
      atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant&#xD;
      tachycardia (AVRT) with manifest (WPW syndrome) or concealed accessory pathways.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      One group undergoes manual ablation using standard non-irrigated ablation catheters and the&#xD;
      other group undergoes manual ablation with an open-irrigated ablation catheter equipped with&#xD;
      CF- sensing (and utilized in a non-irrigated mode during ablation)&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      The main study endpoint is the difference in RF application number during the procedures of&#xD;
      AVNRT/WPW-AVRT ablation; secondary endpoints are differences in RF application rate, acute&#xD;
      success rate, long-term recurrence rate (1 year) major/minor complication rate, and total&#xD;
      procedure/fluoroscopy time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">March 20, 2021</completion_date>
  <primary_completion_date type="Actual">March 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of radiofrequency applications</measure>
    <time_frame>From the beginning till the end of the ablation procedure</time_frame>
    <description>The number of radiofrequency applications during the ablation procedures of AVNRT and WPW-AVRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall duration of radiofrequency applications</measure>
    <time_frame>From the beginning till the end of the ablation procedure</time_frame>
    <description>total of time spend from the beginning till the end of the ablation procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term procedural success</measure>
    <time_frame>At 12 months</time_frame>
    <description>Free from recurrence of pre-excitation or the same clinical type of paroxysmal supraventricular tachycardia (AVNRT or AVRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success/failure</measure>
    <time_frame>at the end of the ablation procedure</time_frame>
    <description>non-inducibility of clinical arrhythmia verified at the end of the standard EP study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time</measure>
    <time_frame>From the beginning till the end of the ablation procedure</time_frame>
    <description>total time for fluoroscopy time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of procedure</measure>
    <time_frame>From the beginning till the end of the ablation procedure</time_frame>
    <description>total time for duration of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Serious) Adverse Events</measure>
    <time_frame>Till 12 months</time_frame>
    <description>all reported SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of AVNRT/WPW-AVRT</measure>
    <time_frame>up till 12 months</time_frame>
    <description>if recurrence of AVNRT/WPW-AVRT, time to recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Tachycardia; Paroxysmal, Supraventricular</condition>
  <condition>Tachycardia, Supraventricular</condition>
  <arm_group>
    <arm_group_label>CONVENTIONAL group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with supraventricular tachycardia treated with radiofrequency ablation using a standard (non-contact-force sensing) ablation catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTACT-FORCE group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with supraventricular tachycardia treated with radiofrequency ablation using a Contact-Force-sensing ablation catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard catheter ablation</intervention_name>
    <description>Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing</description>
    <arm_group_label>CONVENTIONAL group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contact Force-sensing-based catheter ablation</intervention_name>
    <description>Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter</description>
    <arm_group_label>CONTACT-FORCE group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Referral for electrophysiology study because of pre-excitation on 12-lead surface ECG&#xD;
             and/or documented (or suspected) symptomatic PSVT&#xD;
&#xD;
          -  Identification of AVNRT or WPW-AVRT (with manifest or concealed accessory pathway)&#xD;
             during standard EP study&#xD;
&#xD;
          -  Verbal consent to continue with ablation therapy&#xD;
&#xD;
          -  Informed written consent to be included in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of structural heart disease and/or myocardial ischemia&#xD;
&#xD;
          -  pregnancy (and lack of exclusion of potential pregnancy)&#xD;
&#xD;
          -  age below 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamas Szili-Torok, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Ullah W, Hunter RJ, Haldar S, McLean A, Dhinoja M, Sporton S, Earley MJ, Lorgat F, Wong T, Schilling RJ. Comparison of robotic and manual persistent AF ablation using catheter contact force sensing: an international multicenter registry study. Pacing Clin Electrophysiol. 2014 Nov;37(11):1427-35. doi: 10.1111/pace.12501. Epub 2014 Sep 15.</citation>
    <PMID>25220575</PMID>
  </reference>
  <reference>
    <citation>Gerstenfeld EP. Contact force-sensing catheters: evolution or revolution in catheter ablation technology? Circ Arrhythm Electrophysiol. 2014 Feb;7(1):5-6. doi: 10.1161/CIRCEP.114.001424.</citation>
    <PMID>24550405</PMID>
  </reference>
  <reference>
    <citation>Shurrab M, Di Biase L, Briceno DF, Kaoutskaia A, Haj-Yahia S, Newman D, Lashevsky I, Nakagawa H, Crystal E. Impact of Contact Force Technology on Atrial Fibrillation Ablation: A Meta-Analysis. J Am Heart Assoc. 2015 Sep 21;4(9):e002476. doi: 10.1161/JAHA.115.002476. Review.</citation>
    <PMID>26391136</PMID>
  </reference>
  <reference>
    <citation>Kautzner J, Neuzil P, Lambert H, Peichl P, Petru J, Cihak R, Skoda J, Wichterle D, Wissner E, Yulzari A, Kuck KH. EFFICAS II: optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillation. Europace. 2015 Aug;17(8):1229-35. doi: 10.1093/europace/euv057. Epub 2015 Jun 3.</citation>
    <PMID>26041872</PMID>
  </reference>
  <reference>
    <citation>Kimura M, Sasaki S, Owada S, Horiuchi D, Sasaki K, Itoh T, Ishida Y, Kinjo T, Tomita H, Okumura K. Comparison of lesion formation between contact force-guided and non-guided circumferential pulmonary vein isolation: a prospective, randomized study. Heart Rhythm. 2014 Jun;11(6):984-91. doi: 10.1016/j.hrthm.2014.03.019. Epub 2014 Mar 18.</citation>
    <PMID>24657428</PMID>
  </reference>
  <reference>
    <citation>Kuck KH, Reddy VY, Schmidt B, Natale A, Neuzil P, Saoudi N, Kautzner J, Herrera C, Hindricks G, Jaïs P, Nakagawa H, Lambert H, Shah DC. A novel radiofrequency ablation catheter using contact force sensing: Toccata study. Heart Rhythm. 2012 Jan;9(1):18-23. doi: 10.1016/j.hrthm.2011.08.021. Epub 2011 Aug 26.</citation>
    <PMID>21872560</PMID>
  </reference>
  <reference>
    <citation>Martinek M, Lemes C, Sigmund E, Derndorfer M, Aichinger J, Winter S, Nesser HJ, Pürerfellner H. Clinical impact of an open-irrigated radiofrequency catheter with direct force measurement on atrial fibrillation ablation. Pacing Clin Electrophysiol. 2012 Nov;35(11):1312-8. doi: 10.1111/j.1540-8159.2012.03503.x. Epub 2012 Sep 4.</citation>
    <PMID>22946636</PMID>
  </reference>
  <reference>
    <citation>Natale A, Reddy VY, Monir G, Wilber DJ, Lindsay BD, McElderry HT, Kantipudi C, Mansour MC, Melby DP, Packer DL, Nakagawa H, Zhang B, Stagg RB, Boo LM, Marchlinski FE. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol. 2014 Aug 19;64(7):647-56. doi: 10.1016/j.jacc.2014.04.072.</citation>
    <PMID>25125294</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Tamás Géczy</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Tachycardia, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

